Lilly CEO Dave Ricks is confident in the ability of the company's pill to compete and is preparing for a "full launch" in the ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Researchers reviewed the body mass index of over 11 million Americans.

Using data culled from nearly 11 million people, the researchers found that just over 19% were obese in 1990, compared to ...

The prevalence of obese adults in the United States more than doubled between 1990 and 2022.

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) has launched Wegovy as the world's first oral GLP-1 weight ...

Effective policies needed to combat rising obesity prevalence, researchers urge ...

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

The agreement, to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs is the largest of its ...

Is Obesity Genetic or Environmental? Get All the Details This article was reviewed by Lynn Marie Morski, MD, JD. Key ...

Scientists may have found a new way to spot early signs of obesity, which could lead to novel prevention strategies. A study ...

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...